Our data from the current study demonstrate that repurposing the currently approved FDA drug fenofibrate, a PPAR-α agonist which is used to treat dyslipidemia, might be an effective therapy to prevent PIPN symptoms. This evidence concerns the gene PPARA and metabolic syndrome.